Serbian Association of Dermatovenereologists’ Guidelines for the Diagnosis and Treatment of Psoriasis

1. Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29(1):10–5.10.1016/j.sder.2010.01.00220430302Search in Google Scholar

2. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development for coronary artery calcification. Br J Dermatol. 2007;56(2):271–6.10.1111/j.1365-2133.2006.07562.x17223866Search in Google Scholar

3. Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007;143(2):239–42.10.1001/archderm.143.2.23917310004Search in Google Scholar

4. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.10.1007/s00403-010-1080-1301621720857129Search in Google Scholar

5. Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris - update 2015 - short version EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–94.10.1111/jdv.1335426481193Search in Google Scholar

6. Seité S, Khemis A, Rougier A, Ortonne JP. Emollient for maintenance therapy after topical corticotherapy in mild psoriasis. Exp Dermatol. 2009;18(12):1076–8.10.1111/j.1600-0625.2009.00903.x19453736Search in Google Scholar

7. Murphy G, Reich K. In touch with psoriasis: topical treatments and current guidelines. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):3–8.10.1111/j.1468-3083.2011.04059.x21507077Search in Google Scholar

8. Reich K, Bewley A. What is new in topical therapy for psoriasis? J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):15–20.10.1111/j.1468-3083.2011.04061.x21507079Search in Google Scholar

9. Tanghetti EA. The role of topical vitamin D modulators in psoriasis therapy. J Drugs Dermatol. 2009;8(8 Suppl):s4–8.Search in Google Scholar

10. Van de Kerkhof PC, Barker J, Griffiths CE, Kragballe K, Mason J, Menter A, et al. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol. 2008;22(7):859–70.10.1111/j.1468-3083.2007.02534.x18081748Search in Google Scholar

11. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48(5):760–7.10.1067/mjd.2003.10312734506Search in Google Scholar

12. Yamamoto T, Nishioka K. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol. 2003;13(5):471–3.Search in Google Scholar

13. De Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology. 2010;220(4):329–32.10.1159/000278241Search in Google Scholar

14. Roelofzen JH, Aben KK, Oldenhof UT, Coenraads PJ, Alkemade HA, van de Kerkhof PC, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol. 2010;130(4):953–61.10.1038/jid.2009.389Search in Google Scholar

15. Zanolli MD, Feldman SR. Phototherapy treatment protocols for psoriasis and other phototherapy responsive dermatoses. 2^nd ed. London: Taylor and Francis; 2005.10.3109/9780203010587Search in Google Scholar

16. Ibbotson SH, Bilsland D, Cox NH, Dawe RS, Diffey B, Edwards C, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol.2004;151(2):283–97.10.1111/j.1365-2133.2004.06128.xSearch in Google Scholar

17. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114–35.10.1016/j.jaad.2009.08.026Search in Google Scholar

18. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.10.1016/j.jaad.2009.03.027Search in Google Scholar

19. Nijsten TE, Stern RS. Oral retinoid use reduces cutaneous squamous cell carcinoma risk in patients with psoriasis treated with psoralen-UVA: a nested cohort study. J Am Acad Dermatol. 2003;49(4):644–50.10.1067/S0190-9622(03)01587-1Search in Google Scholar

20. Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB, National Psoriasis Foundation. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol. 2010;62(5):838–53.10.1016/j.jaad.2009.05.01719932926Search in Google Scholar

21. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–50.10.1016/j.jaad.2008.02.03918423260Search in Google Scholar

22. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler DA, et al. British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987–1019.10.1111/j.1365-2133.2009.09505.x19857207Search in Google Scholar

23. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152(6):1304–12.10.1111/j.1365-2133.2005.06688.xSearch in Google Scholar

24. Lecluse LL, Piskin G, Mekkes JR, Bos JD, de Rie MA. Review and expert opinion on prevention and treatment of infliximab-related infusion reactions. Br J Dermatol. 2008;159(3):527–36.10.1111/j.1365-2133.2008.08728.xSearch in Google Scholar

25. Reich K, Griffiths C, Barker J, Chimenti S, Daudén E, Giannetti A, et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology. 2008;217(3):268–75.10.1159/000149970Search in Google Scholar

26. Batchelor JM, Ingram JR, Williams H. Adalimumab vs. methotrexate for the treatment of chronic plaque psoriasis. Arch Dermatol 2009;145(6):704–6.10.1001/archdermatol.2009.104Search in Google Scholar

27. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373(9664):633–40.10.1016/S0140-6736(09)60140-9Search in Google Scholar

28. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–28.10.1056/NEJMoa081065220071701Search in Google Scholar

29. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis - results of two phase 3 trials. N Engl J Med. 2014;371(4):326-38.10.1056/NEJMoa131425825007392Search in Google Scholar

30. Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484-93.10.1111/bjd.1334825132411Search in Google Scholar

31. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176-82.10.1016/j.jaad.2014.07.04825242558Search in Google Scholar

32. Saeki H, Nakagawa H, Ishii T, Morisaki Y, Aoki T, Berclaz PY, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol. 2015;29(6):1148-55.10.1111/jdv.1277325355284Search in Google Scholar

33. Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther. 2016;10:1763-70.10.2147/DDDT.S108115488705327307707Search in Google Scholar